Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma

References

• Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-031178151
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Petersson F. Nasopharyngeal carcinoma: a review. Semin Diagn Pathol. 2015;32(1):54–73.25769204
   PubMed Web of Science ®Google Scholar
• Lee HM, Okuda KS, González FE, Patel V. Current perspectives on nasopharyngeal carcinoma. Adv Exp Med Biol. 2019;1164:11–34.31576537
   PubMed Web of Science ®Google Scholar
• Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc B Biol Sci. 2017;72(1732):20160270. doi:10.1098/rstb.2016.0270
   Web of Science ®Google Scholar
• Bei JX, Li Y, Jia WH, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010;42(7):599–603. doi:10.1038/ng.60120512145
   PubMed Web of Science ®Google Scholar
• Lam WKJ, Chan JYK. Recent advances in the management of nasopharyngeal carcinoma. F1000Res. 2018;7:F1000 Faculty Rev-1829. doi:10.12688/f1000research.15066.1
   Google Scholar
• Lee AW, Ma BB, Ng WT, et al. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356–3364. doi:10.1200/JCO.2015.60.934726351355
   PubMed Web of Science ®Google Scholar
• Sun XS, Li XY, Chen QY, et al. Future of radiotherapy in nasopharyngeal carcinoma. Br J Radiol. 2019;92(1102):20190209. doi:10.1259/bjr.2019020931265322
   PubMed Web of Science ®Google Scholar
• Guan S, Wei J, Huang L, et al. Chemotherapy and chemo-resistance in nasopharyngeal carcinoma. Eur J Med Chem. 2020;207:112758. doi:10.1016/j.ejmech.2020.11275832858472
   PubMed Web of Science ®Google Scholar
• Farias TP, Dias FL, Lima RA, et al. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129(7):794–799. doi:10.1001/archotol.129.7.79412874084
   PubMedGoogle Scholar
• Paul P, Deka H, Malakar AK, et al. Nasopharyngeal carcinoma: understanding its molecular biology at a fine scale. Eur J Cancer Prev. 2018;27(1):33–41. doi:10.1097/CEJ.000000000000031427748661
   PubMed Web of Science ®Google Scholar
• Ens EAR, Irekeola AA, Yean Yean C. Diagnostic and prognostic indications of nasopharyngeal carcinoma. Diagnostics. 2020;10(9):611. doi:10.3390/diagnostics10090611
   Web of Science ®Google Scholar
• Liu Z, Yu KJ, Coghill AE, et al. Multilaboratory assessment of Epstein-Barr virus serologic assays: the case for standardization. J Clin Microbiol. 2019;57(11):e01107–e01119. doi:10.1128/JCM.01107-1931434722
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhao W, Lin L, et al. Nasopharyngeal Epstein-Barr virus load: an efficient supplementary method for population-based nasopharyngeal carcinoma screening. PLoS One. 2015;10(7):e0132669. doi:10.1371/journal.pone.013266926151639
   PubMed Web of Science ®Google Scholar
• Guo J, Cui Z, Zheng Y, et al. Comparison of Epstein-Barr virus serological tools for the screening and risk assessment of nasopharyngeal carcinoma: a large population-based study. Pathol Oncol Res. 2020;26(4):2185–2190. doi:10.1007/s12253-020-00808-032222897
   PubMed Web of Science ®Google Scholar
• Li S, Deng Y, Li X, et al. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis. Chin Med J. 2010;123(9):1201–1205.20529563
   PubMed Web of Science ®Google Scholar
• Chen Y, Xin X, Cui Z, et al. Diagnostic value of serum Epstein-Barr virus capsid antigen-IgA for nasopharyngeal carcinoma: a meta-analysis based on 21 studies. Clin Lab. 2016;62(6):1155–1166. doi:10.7754/Clin.Lab.2015.15112227468579
   PubMed Web of Science ®Google Scholar
• Tan LP, Tan GW, Sivanesan VM, et al. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma. Int J Cancer. 2020;146(8):2336–2347. doi:10.1002/ijc.3265631469434
   PubMed Web of Science ®Google Scholar
• Chan KCA, Woo JKS, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513–522. doi:10.1056/NEJMoa170171728792880
   PubMed Web of Science ®Google Scholar
• Mao M, Wang X, Sheng H, et al. Heat shock protein 90α provides an effective and novel diagnosis strategy for nasopharyngeal carcinoma. Adv Ther. 2021;38(1):413–422. doi:10.1007/s12325-020-01518-433141414
   PubMed Web of Science ®Google Scholar
• Puri KS, Suresh KR, Gogtay NJ, et al. Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med. 2009;55(2):131–134. doi:10.4103/0022-3859.5284619550060
   PubMed Web of Science ®Google Scholar
• Wei KR, Xu Y, Liu J, et al. Histopathological classification of nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2011;12(5):1141–1147.21875256
   PubMedGoogle Scholar
• Guo R, Mao YP, Tang LL, et al. The evolution of nasopharyngeal carcinoma staging. Br J Radiol. 2019;92(1102):20190244. doi:10.1259/bjr.2019024431298937
   PubMed Web of Science ®Google Scholar
• Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2015;12(1):11–26. doi:10.1038/nrclinonc.2014.19225403939
   PubMed Web of Science ®Google Scholar
• Zhang SQ, Pan SM, Liang SX, et al. Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics. Int J Oncol. 2021;8(4):9. doi:10.3892/ijo.2021.5188
   Web of Science ®Google Scholar
• Ma BBY, Chen YP, Hui EP, et al. Recent advances in the development of biomarkers and chemoradiotherapeutic approaches for nasopharyngeal carcinoma. Am Soc Clin Oncol Educ Book. 2020;40:1–11. doi:10.1200/EDBK_280747
   PubMedGoogle Scholar
• Gao R, Wang L, Liu Q, et al. Evaluation of seven recombinant VCA-IgA ELISA kits for the diagnosis of nasopharyngeal carcinoma in China: a case-control trial. BMJ Open. 2017;7(6):e013211. doi:10.1136/bmjopen-2016-013211
   PubMed Web of Science ®Google Scholar
• Fung SY, Lam JW, Chan KC. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma. Chin Clin Oncol. 2016;5(2):18. doi:10.21037/cco.2016.03.0727121878
   PubMedGoogle Scholar
• Zhang G, Li Z, Zhou Q. Utility of serum EB virus Zta antibody in the diagnostic of nasopharyngeal carcinoma: evidences from 2,126 cases and 15,644 controls. Front Oncol. 2019;9:1391. doi:10.3389/fonc.2019.0139131921648
   PubMed Web of Science ®Google Scholar
• Feng Y, Xia W, He G, et al. Accuracy evaluation and comparison of 14 diagnostic markers for nasopharyngeal carcinoma: a meta-analysis. Front Oncol. 2020;10:1779. doi:10.3389/fonc.2020.0177933072558
   PubMed Web of Science ®Google Scholar
• Martine P, Rébé C. Heat shock proteins and iInflammasomes. Int J Mol Sci. 2019;20(18):4508. doi:10.3390/ijms20184508
   PubMed Web of Science ®Google Scholar
• Li Z, Srivastava P. Heat-shock proteins. Curr Protoc Immunol. 2004. doi:10.1002/0471142735.ima01ts58
   PubMedGoogle Scholar
• Zuehlke AD, Moses MA, Neckers L. Heat shock protein 90: its inhibition and function. Philos Trans R Soc B Biol Sci. 2018;373(1738):20160527. doi:10.1098/rstb.2016.0527
   PubMed Web of Science ®Google Scholar
• Hoter A, El-Sabban ME, Naim HY. The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci. 2018;19(9):2560. doi:10.3390/ijms19092560
   PubMed Web of Science ®Google Scholar
• Wang X, Song X, Zhuo W, et al. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A. 2009;106(50):21288–21293. doi:10.1073/pnas.090815110619965370
   PubMed Web of Science ®Google Scholar
• Zeng Z, Fan S, Zhang X, et al. Epstein-Barr virus-encoded small RNA 1 (EBER-1) could predict good prognosis in nasopharyngeal carcinoma. Clin Transl Oncol. 2016;18(2):206–211. doi:10.1007/s12094-015-1354-326260913
   PubMed Web of Science ®Google Scholar
• Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537–549. doi:10.1038/nrc288720651736
   PubMed Web of Science ®Google Scholar
• Lee HW, Kim KM. Clinical significance of heat shock protein 90α expression as a biomarker of prognosis in patients with gastric cancer. Niger J Clin Pract. 2019;22(12):1698–1705. doi:10.4103/njcp.njcp_68_1931793477
   PubMed Web of Science ®Google Scholar
• Nouri-Vaskeh M, Alizadeh L, Hajiasgharzadeh K, et al. The role of HSP90 molecular chaperones in hepatocellular carcinoma. J Cell Physiol. 2020;235(12):9110–9120. doi:10.1002/jcp.2977632452023
   PubMed Web of Science ®Google Scholar
• Kasanga M, Liu L, Xue L, et al. Plasma heat shock protein 90-alpha have an advantage in diagnosis of colorectal cancer at early stage. Biomark Med. 2018;12(8):881–890. doi:10.2217/bmm-2018-015529939072
   PubMed Web of Science ®Google Scholar
• Ye M, Huang W, Wu WW, et al. FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition. Oncotarget. 2017;8(9):15364–15376. doi:10.18632/oncotarget.1497028157708
   PubMedGoogle Scholar
• Zhang PC, Liu X, Li MM, et al. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo. Biochem Pharmacol. 2020;172:113771. doi:10.1016/j.bcp.2019.11377131863779
   PubMed Web of Science ®Google Scholar
• Liu F, Wang L, Yi S, et al. Clinical and biological significances of heat shock protein 90 (Hsp90) in human nasopharyngeal carcinoma cells and anti-cancer effects of Hsp90 inhibitor. Biomed Pharmacother. 2019;120:109533. doi:10.1016/j.biopha.2019.10953331634779
   PubMed Web of Science ®Google Scholar
• Feng J, Xie G, Zhan Y, et al. Elevated HSP90 associates with expression of HIF-1α and p-AKT and is predictive of poor prognosis in nasopharyngeal carcinoma. Histopathology. 2019;75(2):202–212. doi:10.1111/his.1386230882922
   PubMed Web of Science ®Google Scholar
• Song C, Yang S. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of nasopharyngeal carcinoma. Pak J Med Sci. 2013;29(3):885–890. doi:10.12669/pjms.293.290724353651
   PubMed Web of Science ®Google Scholar
• Liu W, Chen G, Gong X, et al. The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis. Cancer Cell Int. 2021;1(1):164. doi:10.1186/s12935-021-01862-7
   Web of Science ®Google Scholar
• Fu Y, Xu X, Huang D, et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an official, large-scale, and multicenter clinical trial. EBioMedicine. 2017;24:56–63. doi:10.1016/j.ebiom.2017.09.00728939487
   PubMed Web of Science ®Google Scholar
• Stivarou T, Stellas D, Vartzi G, et al. Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo. Cancer Biol Ther. 2016;17(8):799–812. doi:10.1080/15384047.2016.119504127259689
   PubMed Web of Science ®Google Scholar
• Klimczak M, Biecek P, Zylicz A, et al. Heat shock proteins create a signature to predict the clinical outcome in breast cancer. Sci Rep. 2019;9(1):7507. doi:10.1038/s41598-019-43556-131101846
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ni L, Li Q, et al. Diagnostic, clinicopathologic, therapeutic and prognostic value of plasma heat shock protein 90 levels in patients with advanced gastrointestinal carcinoma. J Cancer. 2020;11(20):5890–5899. doi:10.7150/jca.4634332922531
   PubMed Web of Science ®Google Scholar
• Mittal S, Rajala MS. Heat shock proteins as biomarkers of lung cancer. Cancer Biol Ther. 2020;21(6):477–485. doi:10.1080/15384047.2020.173648232228356
   PubMed Web of Science ®Google Scholar
• Chan KC, Ting CM, Chan PS, et al. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol Cancer. 2013;12(1):128. doi:10.1186/1476-4598-12-12824156782
   PubMed Web of Science ®Google Scholar
• Kondo S, Horikawa T, Takeshita H, et al. Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients. Cancer Sci. 2004;95(6):508–513. doi:10.1111/j.1349-7006.2004.tb03241.x15182432
   PubMed Web of Science ®Google Scholar
• Luo YL, Chen H, Peng SG, et al. Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma. Zhonghua Yi Xue Za Zhi. 2013;93(44):3516–3519.24521892
   PubMedGoogle Scholar